IL-2RG (Common Gamma Chain, CD132) Drug Discovery Landscape & Assay Solutions
- By admin
- 12 Aug 2026
- Comments
Comprehensive Market Intelligence for Cytokine Receptor Complex Therapeutics and X-SCID Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
Complete reagent toolkit for IL-2RG (CD132) functional studies and heterotrimeric receptor complex analysis. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-2RG ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View IL-2RG Products |
| Gene Delivery | IL-2RG Lentivirus Premade Particles. Full-length ORF for stable cell line generation. High titer (>10^8 TU/mL). | View IL-2RG Products |
| Benchmark Ab | Anti-IL-2RG Reference Antibody. Recombinant positive control for flow cytometry and blocking assays. | View IL-2RG Products |
| Validator | IL-2RG siRNA Set. For knockdown verification and specificity control in functional assays. | View IL-2RG Products |
| Related Target: IL-2RA | IL-2 Receptor Alpha (CD25). Forms high-affinity trimeric complex with IL-2RG and IL-2RB. Critical for Treg biology. | View IL-2RA Products |
| Related Target: IL-2RB | IL-2 Receptor Beta (CD122). Shared subunit for IL-2 and IL-15 signaling. Essential for heterodimeric complex assembly. | View IL-2RB Products |
| Related Target: IL-15 | Shares the common gamma chain; highly active in NK and CD8+ T cell expansion without Treg bias. | View IL-15 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterotrimeric Complex Assembly (IL-2Rα/β/γ) | Purified IL-2RG ECD-Fc with verified binding capacity for in vitro reconstitution with IL-2RA and IL-2RB |
| Multi-Cytokine Cross-Reactivity (IL-2, IL-4, IL-7, IL-15, IL-21) | Species-specific ortholog proteins (Human/Mouse/Cyno) with sequence-verified extracellular domains |
| X-SCID Mutation Analysis | Custom mutant protein generation (truncation/point mutations) for mechanistic studies |
| Cell-Based Signaling Assays | Lentivirus particles for stable integration preserving native glycosylation and conformation; Validated siRNA for specificity checks in STAT5 phosphorylation assays |
| Receptor Selectivity (Alpha vs Beta/Gamma) | High purity (>95%) IL-2RA, IL-2RB, and IL-2RG ECD proteins available for SPR/Biacore kinetic profiling |
| Lack of Controls & False Positives | Clinical Benchmark Antibodies and validated siRNA included for assay standardization and specificity control |
Live IL-2RG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding IL-2RG (CD132) is bifurcated between rare disease correction and broad immunomodulation. As the shared signaling subunit for six critical cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), IL-2RG represents both a liability in X-linked severe combined immunodeficiency (X-SCID) and a potential target for comprehensive immunosuppression. Current R&D is shifting from first-generation IL-2 muteins toward selective γc cytokine modulation and next-generation gene therapy vectors with improved safety profiles for X-SCID. Meanwhile, the race for engineered cytokines (Muteins) and PEGylated variants is intensifying, focusing on selective intermediate-affinity receptor (IL-2Rβγ) engagement to expand effector T cells while avoiding Treg activation and vascular leak syndrome.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (LVV) | Orchard Therapeutics, Academic Centers | X-SCID | Functional Receptor Restoration (Need full-length Lentivirus for transduction efficiency assays) |
| Recombinant Cytokines | ImmunityBio (N-803/IL-15), Altor BioScience | Solid Tumors, Viral Infections | Receptor Binding Competition (Need high-purity IL-2RG ECD-Fc with IL-2RB for heterodimer binding) |
| Cell Therapy Support | Multiple CROs & Biotechs | CAR-T Expansion, TIL Therapy | Receptor Density Quantification (Need calibrated reference antibodies and proteins) |
| Immunosuppressive Biologics | Preclinical/Academic | Autoimmune Diseases, Transplant | Multi-Cytokine Blocking Panel (Need IL-2RG proteins for IL-2, IL-4, IL-7, IL-15, IL-21 competition assays) |
| Engineered Cytokine (Muteins) | Sanofi, Alkermes, Medicenna | Solid Tumors | Selectivity Assay (Need High-Purity IL-2RB/IL-2RG ECDs) |
| Cytokine-Antibody Fusion | Roche, Nektar | Advanced Malignancies | Binding Kinetics (Need Native Glycosylation Proteins) |